Wake up daily to our latest coverage of business done better, directly in your inbox.
Get your weekly dose of analysis on rising corporate activism.
The best of solutions journalism in the sustainability space, published monthly.
Select Newsletter
By signing up you agree to our privacy policy. You can opt out anytime.
British pharmaceutical company GlaxoSmithKline (GSK) has unveiled possibly the world’s first malaria vaccine following “significant” results from an ongoing clinical trial. Researchers reported at a malaria conference in Durban, South Africa, that the jab continues to protect a substantial proportion of babies and young children 18 months after vaccination.
GSK said it would apply for a licence from the European Medicines Agency next year. If the vaccine – code-named RTS,S – is confirmed to be safe and effective, the World Health Organisation has indicated that it will support use of the vaccine as soon as 2015.
The company has also vowed to sell the vaccine at cost price plus 5%, which it said would fund further research into tropical diseases.
The development of the jab has been jointly funded by GSK and Bill and Melinda Gates through the PATH Malaria Vaccine Initiative.
TriplePundit has published articles from over 1000 contributors. If you'd like to be a guest author, please get in touch!
